JUN-13-13 The Thailand Ministry of Health and CDC published results from a randomized controlled trial of a daily oral dose of 300 mg of tenofovir disoproxil fumarate (TDF) that showed efficacy in reducing the acquisition of HIV infection among injecting drug users. Based on these findings, CDC recommends that preexposure prophylaxis (PrEP) be considered as one of several prevention options for persons at very high risk for HIV acquisition through the injection of illicit drugs. Click here to view the updated guidance in the MMWR and click here to view the Lancet article .
MAY-17-13 Please join the Forum in congratulating Nina Mani on an exciting new career move. Nina is leaving the Forum, but she is not going far – starting June 3 she will join the FDA Center for Drug Evaluation Research, Division of Antiviral Products. That we will miss her is the understatement of the century. But the offer to join our colleagues at the FDA as a project manager presented a phenomenal opportunity – an excellent fit for her career path. We congratulate Jeff, Kim, Jules and Patrick on an excellent choice! We imagine that many of you will have the pleasure of interacting with her in her new capacity.
MAY-16-13 Dr. Howard Koh, the Assistant Secretary for Health,
announced on May 16 that
the partner agencies are committed and dedicated to renewing the Action Plan
for another three years and are currently working on their vision and
priorities for 2014-2016.
The 2012 National Summit on HIV and Viral Hepatitis Diagnosis,
Prevention, and Access
Care (November 26-28, 2012, Washington, DC) is sponsored by
for Collaborative HIV Research in partnership with the American Academy of HIV Medicine, amfAR, the American Academy of Nursing, the Hepatitis B Project, the Hepatitis Education
Project, the HIV Medicine Association, Kaiser Permanente, the National
Association of Community Health Centers, the NIH-NIAID Division of Acquired Immunodeficiency Syndrome, the National Black Gay Men's Advocacy Coalition, the National Viral
Hepatitis Roundtable, and the Office of HIV/AIDS and Infectious Disease Policy (HHS).
The mission of the 2012 Summit is to support improvement in HIV
and viral hepatitis testing, prevention, and linkage to care in the
United States. The nation’s public health scientific and advocacy
leadership will meet to discuss state-of-the-art mechanisms to support
the “National HIV/AIDS Strategy” and the HHS “Action Plan for the
Prevention, Care and Treatment of Viral Hepatitis.”
The program is being developed under the leadership of the
Dr. John G. Bartlett (Johns Hopkins University), Dr. Kenneth H.
(The Fenway Institute), and Dr. Veronica Miller (the Forum for Collaborative HIV Research), the Organizing Committee and the Scientific Advisory Committee
governmental agencies, professional societies, academia, clinical
community and advocacy organizations, and industry.
program will consist of plenary sessions and breakout sessions
in the areas of Routine and Expanded Testing, Prevention Models, Outcomes
and Impact Evaluation, and Access, Linkage and Retention in Care.
Goals and Objectives of the 2012 Summit are:
To address and support the
continued implementation of recommendations for increased HIV and viral
To further identify strategies
for reducing new HIV and viral hepatitis infections, increase access to
care and treatment, reduce related health disparities and reduce the
public health burden of HIV and viral hepatitis.
To strengthen viral hepatitis
surveillance, increase awareness and coverage of vaccine-preventable viral
To assess the current impact of differing
recommendations to implement routine HIV and viral hepatitis testing on
policy, program and practice at the local, state and federal level.
The 2012 Summit was held November 26-28, 2012 in Washington, DC.